Physiological or pathological - A role for relaxin in the cardiovascular system?

Current Opinion in Pharmacology

Volumn 3, Issue 2, 2003, Pages 152-158

  Samuel, Chrishan S ^a   Parry, Laura J ^a   Summers, Roger J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; G PROTEIN COUPLED RECEPTOR; LEUCINE; LIGAND; POLYPEPTIDE; RELAXIN;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DRUG SYNTHESIS; ENDOCRINE SYSTEM; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HEART FAILURE; HEART FUNCTION; HUMAN; MOLECULAR CLONING; MOUSE; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HEART; HUMANS; PHENOTYPE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN;

EID: 0037385601     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00011-0     Document Type: Review

References (60)

1. Hisaw FL: Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med 1926, 23:661-663.
2. Sherwood OD: Relaxin. In The Physiology of Reproduction, edn 2. Edited by Knobil E, Neill JD. New York: Raven Press Ltd; 1994:861-1009.
3. Carrell DT, Peterson C, Urry RL: The binding of recombinant human relaxin to human spermatozoa. Endocrinology Research 1995, 21:697-707.
4. Bani D: Relaxin: a pleiotropic hormone. Gen Pharmacol 1997, 28:13-22.
5. Parry LJ, Poterski R, Summerlee AJS, Jones SA: Mechanism of the haemotensive action of a porcine relaxin in anaesthetised rats. J Neuroendocrinol 1990, 2:53-58.
6. Novak J, Danielson LA, Kerchner LJ, Sherwood OD, Ramirez RJ, Moalli PA, Conrad KP: Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 2001, 107:1469-1475.
7. Weisinger RS, Burns P, Eddie LW, Wintour EM: Relaxin alters the plasma osmolality-arginine vasopressin relationship in the rat. J Endocrinol 1993, 137:505-510.
8. Dayanithi G, Cazalis M, Nordmann JJ: Relaxin affects the release of oxytocin and vasopressin from the neurohypophysis. Nature 1987, 325:813-816.
9. Geddes BJ, Summerlee AJ: The emerging concept of relaxin as a centrally acting peptide hormone with hemodynamic actions. J Neuroendocrinol 1995, 7:411-417.
10. Sunn N, EgliM, Burazin TC, Burns P, Colvill L, Davern P, Denton DA, Oldfield BJ, Weisinger RS, Rauch M et al.: Circulating relaxin acts on subfornical organ neurons to stimulate water drinking in the rat. Proc Natl Acad Sci USA 2002, 99:1701-1706.
11. Geddes BJ, Parry LJ, Summerlee AJ: Brain angiotensin-II partially mediates the effects of relaxin on vasopressin and oxytocin release in anesthetized rats. Endocrinology 1994, 134:1188-1192.
12. McKinley MJ, Allen AM, May CN, McAllen RM, Oldfield BJ, Sly D, Mendelsohn FA: Neural pathways from the lamina terminalis influencing cardiovascular and body fluid homeostasis. Clin Exp Pharmacol Physiol 2001, 28:990-992.
13. Osheroff PL, Phillips HS: Autoradiographic localization of relaxin binding sites in rat brain. Proc Natl Acad Sci USA 1991, 88:6413-6417.
14. Osheroff PL, Cronin MJ, Lofgren JA: Relaxin binding in the rat heart atrium. Proc Natl Acad Sci USA 1992, 89:2384-2388.
15. Parry LJ, Wilson BC, Poterski RS, Summerlee AJ: The cardiovascular effects of porcine relaxin in Brattleboro rats. Endocrine 1998, 8:317-322.
16. Kakouris H, Eddie LW, Summers RJ: Cardiac effects of relaxin in rats. Lancet 1992, 339:1076-1078.
17. Coulson CC, Thorp JM Jr, Mayer DC, Cefalo RC: Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol 1996, 87:610-612.
18. Tan YY, Wade JD, Tregear GW, Summers RJ: Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues. Br J Pharmacol 1998, 123:762-770.
19. Piedras-Renteria ES, Sherwood OD, Best PM: Effects of relaxin on rat atrial myocytes. I. Inhibition of I(to) via PKA-dependent phosphorylation. Am J Physiol 1997, 272:H1791-H1797.
20. Kompa AR, Samuel CS, Summers RJ: Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol 2002, 137:710-718.
21. Toth M, Taskinen P, Ruskoaho H: Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J Endocrinol 1996, 150:487-495.
22. BaniSacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E: Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995, 116:1589-1594.
23. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB: Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol 1998, 152:1367-1376.
24. Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C, McMurray J: Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 2002, 106:292-295.
25. Reid JJ, Tran N-H, Tregear GW, Roche PJ: The effect of relaxin on vascular function in rat aorta. In Relaxin 2000. Edited by Tregear GW, Ivell R, Bathgate RA, Wade JD. Dordrecht: Kluwer Academic Publishers; 2001:183-184.
26. Bigazzi M, Bani D, Sacchi TB: Relaxin: a possible future preventive therapy for cardiovascular disease in postmenopausal women and men? Climacteric 2001, 4:137-143.
27. . Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB, Bani D: Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J 2002, 16:252-254.
28. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB: Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 1997, 138:4713-4720.
29. Sherwood OD, Olson LM, Zhao S, Little HR: Inhibition of nitric oxide synthase activity diminishes the acute effects of relaxin on growth, but not softening, of the cervix in the rat. Endocrinology 2000, 141:2458-2464.
30. Han X, Habuchi Y, Giles WR: Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells. Circ Res 1994, 74:537-541.
31. Piedras-Renteria ES, Sherwood OD, Best PM: Effects of relaxin on rat atrialmyocytes. II. Increased calcium influx derived from action potential prolongation. Am J Physiol 1997, 272:H1798-H1803.
32. Summerlee AJ, Parry LJ: Beta-adrenoceptors partially mediate the cardiac effects of porcine relaxin in anaesthetised rats. Biol Reprod 1993, 48(Suppl):31.
33. Danielson LA, Sherwood OD, Conrad KP: Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999, 103:525-533.
34. Novak J, Ramirez RJ, Gandley RE, Sherwood OD, Conrad KP: Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol Regul Integr Comp Physiol 2002, 283:R349-R355.
35. Gandley RE, Conrad KP, McLaughlin MK: Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1-R7.
36. Skott O, Carter AM: Relaxin is a vasodilator hormone. Am J Physiol Regul Integr Comp Physiol 2002, 283:R347-R348.
37. Dschietzig T, Richter C, Bartsch C, Bohme C, Heinze D, Ott F, Zartnack F, Baumann G, Stangl K: Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun 2001, 289:245-251.
38. Tan YY, Wade JD, Tregear GW, Summers RJ: Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment. Br J Pharmacol 1999, 127:91-98.
39. Osheroff PL, Ho WH: Expression of relaxin mRNA and relaxin receptors in postnatal and adult rat brains and hearts. Localization and developmental patterns. J Biol Chem 1993, 268:15193-15199.
40. 32P-labeled human relaxin to human uterine cells and primary rat atrial cardiomyocytes. Endocrinology 1995, 136:4377-4381.
41. Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, van der Spek PJ, van Duin M, Hsueh AJ: The three subfamilies of leucine-rich repeat-containing G-protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 2000, 14:1257-1271.
42. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ: Activation of orphan receptors by the hormone relaxin. Science 2002, 295:671-674.
43. Mayerhofer A, Engling R, Stecher B, Ecker A, Sterzik K, Gratzl M: Relaxin triggers calcium transients in human granulosa-lutein cells. Eur J Endocrinol 1995, 132:507-513.
44. Noack T, Edwards G, Deitmer P, Weston AH: Potassium channel modulation in rat portal vein by ATP depletion: a comparison with the effects of levcromakalim (BRL 38227). Br J Pharmacol 1992, 107:945-955.
45. Bartsch C, Bartlick B, Ivell R: Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. Mol Hum Reprod 2001, 7:799-809.
46. Bathgate RA, Samuel CS, Burazin TC, Layfield S, Claasz AA, Reytomas IG, Dawson NF, Zhao C, Bond C, Summers RJ et al.: Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem 2002, 277:1148-1157.
47. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, Stangl K: The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001, 15:2187-2195.
48. Hudson P, Haley J, John M, Cronk M, Crawford R, Haralambidis J, Tregear G, Shine J, Niall H: Structure of a genomic clone encoding biologically active human relaxin. Nature 1983, 301:628-631.
49. Hudson P, John M, Crawford R, Haralambidis J, Scanlon D, Gorman J, Tregear G, Shine J, Niall H: Relaxin gene expression in human ovaries and the predicted structure of a human preprorelaxin by analysis of cDNA clones. EMBO J 1984, 3:2333-2339.
50. Gunnersen JM, Crawford RJ, Tregear GW: Expression of the relaxin gene in rat tissues. Mol Cell Endocrinol 1995, 110:55-64.
51. Taylor MJ, Clark CL: Evidence for a novel source of relaxin: atrial cardiocytes. J Endocrinol 1994, 143:R5-R8.
52. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate R, Hsueh AJ: H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem 2002, in press.
53. Zhao L, Roche PJ, Gunnersen JM, Hammond VE, Tregear GW, Wintour EM, Beck F: Mice without a functional relaxin gene are unable to deliver milk to their pups. Endocrinology 1999, 140:445-453.
54. Du X-J, Samuel CS, Gao X-M, Zhao L, Parry LJ, Tregear GW: Increased myocardial collagen and ventricular diastolic dysfunction in relaxin-deficient mice: a gender-specific phenotype. Cardiovasc Res 2003, 57:395-404.
55. Unemori EN, Amento EP: Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990, 265:10681-10685.
56. Unemori EN, Beck LS, Lee WP, Xu Y, Siegel M, Keller G, Liggitt HD, Bauer EA, Amento EP: Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993, 101:280-285.
57. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP: Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996, 98:2739-2745.
58. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G: Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 2001, 59:876-882.
59. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, Unemori EN, Iredale JP: Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001, 49:577-583.
60. Samuel CS, Zhao CZ, Bathgate RAD, Bond CP, Burton MD, Parry LJ, Summers RJ, Tang MLK, Amento EP, Tregear GW: Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003, 17:121-123.